GlassScriptPhysician profile
Danielle D Schmachtenberger
NPI 1538119177
$1,501.40
in general payments reported to CMS, 2019-2025
28 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $90.00 · 2022: $395 · 2023: $491 · 2024: $242 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,016.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,016.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $242.83 | 2021-2023 | Imbruvica |
| Inari Medical, INC. | $185.15 | 2022 | |
| Abbvie INC. | $96.77 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.45 | 2022-2025 | Iclusig |
| Lilly USA, LLC | $89.23 | 2023-2025 | Jaypirca, Verzenio |
| Sumitomo Pharma America, INC. | $75.11 | 2023-2024 | Orgovyx |
| Incyte Corporation | $70.39 | 2022-2024 | Jakafi |
| Sobi, INC | $56.59 | 2023-2024 | |
| Ipsen Biopharmaceuticals, INC | $55.02 | 2023-2024 | Onivyde, Tazverik |
| Beone Medicines USA, INC. | $54.82 | 2025 | Brukinsa |
| Celgene Corporation | $47.44 | 2022 | |
| Springworks Therapeutics, INC. | $40.93 | 2024-2025 | Ogsiveo |
| Genzyme Corporation | $40.74 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $39.79 | 2023 | Opdivo |
| Emd Serono, INC. | $36.46 | 2023-2025 | Bavencio |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30.68 | 2025 | Keytruda, Lynparza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.93 | 2025 | |
| Genentech USA, INC. | $26.18 | 2023 | Lunsumio, Polivy, Columvi |
| Eisai INC. | $24.51 | 2025 | |
| Alexion Pharmaceuticals, INC. | $23.84 | 2023 | Ultomiris |
| Seagen INC. | $20.65 | 2023 | Tukysa |
| Novartis Pharmaceuticals Corporation | $18.96 | 2023 | |
| Rigel Pharmaceuticals, INC. | $18.54 | 2023 | Rezlidhia, Tavalisse |
| Stemline Therapeutics INC. | $18.54 | 2023 | Orserdu |
| Astrazeneca Pharmaceuticals LP | $17.79 | 2023 | Lynparza |
| Bayer Healthcare Pharmaceuticals INC. | $16.50 | 2023 | |
| Foundation Medicine, INC. | $16.18 | 2023 | Foundationone Cdx |
| Mirati Therapeutics, INC. | $14.38 | 2023 | Krazati |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Schmachtenberger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.